专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060264453A1 Rapamycin formulations and methods of their use 有权
标题翻译：雷帕霉素配方及其使用方法
公开(公告)号：US20060264453A1
公开(公告)日：2006-11-23
申请号：US11352092
申请日：2006-02-09
申请人： Sreenivasu Mudumba , Philippe Dor , Thierry Nivaggioli , David Weber , Sidiq Farooq
发明人： Sreenivasu Mudumba , Philippe Dor , Thierry Nivaggioli , David Weber , Sidiq Farooq
IPC分类号： A61K31/4745 , A61K31/045
CPC分类号： A61K9/0046 , A61K9/0019 , A61K9/0048 , A61K31/045 , A61K31/436 , A61K31/44 , A61K31/4745 , A61K47/10 , A61K47/12 , A61K47/44
摘要： Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.
摘要翻译：本文描述的是液体雷帕霉素制剂。本文描述了使用本文所述的液体雷帕霉素制剂治疗或预防疾病或病症如脉络膜新生血管形成，湿性AMD和干性AMD的方法，以及防止干性AMD转变为湿性AMD。

2. 发明申请

US20060258698A1 Liquid formulations for treatment of diseases or conditions 审中-公开
公开(公告)号：US20060258698A1
公开(公告)日：2006-11-16
申请号：US11351761
申请日：2006-02-09
申请人： Sreenivasu Mudumba , Philippe Dor , Thierry Nivaggioli , David Weber , Sidiq Farooq
发明人： Sreenivasu Mudumba , Philippe Dor , Thierry Nivaggioli , David Weber , Sidiq Farooq
IPC分类号： A61K31/4745
CPC分类号： A61K9/0046 , A61K9/0019 , A61K9/0048 , A61K31/045 , A61K31/436 , A61K31/44 , A61K31/4745 , A61K47/10 , A61K47/12 , A61K47/44
摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The liquid formulations may comprise rapamycin or other therapeutic agents.

3. 发明申请

US20060257450A1 Drug delivery systems for treatment of diseases or conditions 审中-公开
标题翻译：用于治疗疾病或病症的药物输送系统
公开(公告)号：US20060257450A1
公开(公告)日：2006-11-16
申请号：US11386290
申请日：2006-03-21
申请人： Sreenivasu Mudumba , Philippe Jm Dor , Thierry Nivaggioli , David Weber , Sidiq Farooq
发明人： Sreenivasu Mudumba , Philippe Jm Dor , Thierry Nivaggioli , David Weber , Sidiq Farooq
IPC分类号： A61K31/4745 , A61F2/02
CPC分类号： A61K9/0051 , A61K31/436 , A61K31/4745
摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are solid drug delivery systems and methods for providing extended delivery of therapeutic agents to such tissues. A solid drug delivery system may be placed in a subject, including but not limited to placement between the sclera and the conjunctiva or transscleral placement. Described methods may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, age-related macular degeneration, or wet age-related macular degeneration in a subject. The solid drug delivery devices may comprise rapamycin or other therapeutic agents. Also described are methods of treating ocular diseases or disorders by administering an antiproliferative agent, including but not limited to rapamycin, proximal to an ocular device.
摘要翻译：包括但不限于眼睛中的组织的疾病和病症可被有效治疗，预防，抑制，发作延迟或由给予这些组织的治疗剂引起的回归。本文描述的是用于向这些组织提供治疗剂的延长递送的固体药物递送系统和方法。固体药物递送系统可以放置在受试者中，包括但不限于在巩膜和结膜之间的放置或经巩膜放置。描述的方法可用于施用雷帕霉素以治疗或预防受试者的血管生成，脉络膜新生血管形成，年龄相关性黄斑变性或湿性年龄相关性黄斑变性。固体药物递送装置可以包含雷帕霉素或其它治疗剂。还描述了通过在近视眼装置上施用抗增生剂（包括但不限于雷帕霉素）来治疗眼部疾病或病症的方法。

4. 发明申请

US20060182771A1 Formulations for ocular treatment 审中-公开
标题翻译：眼部治疗剂型
公开(公告)号：US20060182771A1
公开(公告)日：2006-08-17
申请号：US11351844
申请日：2006-02-09
申请人： Philippe Dor , Sreenivasu Mudumba , Thierry Nivaggioli , David Weber
发明人： Philippe Dor , Sreenivasu Mudumba , Thierry Nivaggioli , David Weber
IPC分类号： A61K31/4745 , A61K9/00
CPC分类号： A61K9/0046 , A61K9/0019 , A61K9/0048 , A61K31/045 , A61K31/436 , A61K31/44 , A61K31/4745 , A61K47/10 , A61K47/12 , A61K47/44
摘要： Diseases and conditions associated with tissues of the body, including tissues in the eye, can be effectively treated by administering therapeutic agents to those tissues. Described herein are self-emulsifying formulations and methods for delivering therapeutic agents to such tissues. A self-emulsifying formulation may be delivered to an aqueous medium of a subject, including but not limited to the vitreous. A method may, for instance, be used to administer rapamycin or related compounds to treat or prevent choroidal neovascularization associated with age-related macular degeneration, or to treat dry AMD. A self-emulsifying formulation may also be administered systemically, such as orally, to treat transplant rejection in a subject. A self-emulsifying formulation may comprise rapamycin, related compounds, or other therapeutic agents.
摘要翻译：可以通过向这些组织施用治疗剂来有效地治疗与身体组织（包括眼睛中的组织）相关的疾病和病症。本文描述了将治疗剂递送到这种组织的自乳化制剂和方法。自乳化制剂可以递送到受试者的水性介质，包括但不限于玻璃体。例如，可以使用方法来施用雷帕霉素或相关化合物以治疗或预防与年龄相关性黄斑变性相关的脉络膜新血管形成，或治疗干性AMD。自乳化制剂也可以全身施用，例如口服给药以治疗受试者的移植排斥。自乳化制剂可以包含雷帕霉素，相关化合物或其它治疗剂。

5. 发明申请

US20070265294A1 Formulations and methods for vascular permeability-related diseases or conditions 有权
标题翻译：血管通透性相关疾病或病症的制剂和方法
公开(公告)号：US20070265294A1
公开(公告)日：2007-11-15
申请号：US11726813
申请日：2007-03-23
申请人： David Kleinman , Thierry Nivaggioli , Mary Gerritsen , David Weber
发明人： David Kleinman , Thierry Nivaggioli , Mary Gerritsen , David Weber
IPC分类号： A61K31/436 , A61P11/00 , A61P25/00 , A61P29/00 , A61P31/12 , A61P31/16 , A61P9/00
CPC分类号： A61K31/436 , A61K47/10
摘要： Described herein are formulations and methods for treating, inhibiting, preventing, delaying onset, or causing regression of a disease or condition relating to vascular permeability.
摘要翻译：本文描述了用于治疗，抑制，预防，延迟发作或引起与血管通透性有关的疾病或病症消退的制剂和方法。

6. 发明申请

US20060204548A1 Microimplants for ocular administration 审中-公开
标题翻译：用于眼部给药的微量植入物
公开(公告)号：US20060204548A1
公开(公告)日：2006-09-14
申请号：US11070158
申请日：2005-03-01
申请人： Thierry Nivaggioli , David Weber
发明人： Thierry Nivaggioli , David Weber
IPC分类号： A61F2/00 , A61K31/56 , A01N45/00
CPC分类号： A61F9/0017 , A61F2210/0004 , A61K9/0051 , A61K9/204
摘要： Implants and microimplants are provided comprising homogeneous mixtures of active ingredient and bioerodible polymer, including microimplants having diameters of 0.019 inches or less and which can be delivered to the eye using self-sealing methods. Methods of manufacturing the implants and microimplants are provided that yield batches of highly uniform implants and microimplants within very narrow tolerance ranges.
摘要翻译：提供植入物和微量植入物，其包括活性成分和生物可腐蚀聚合物的均匀混合物，包括直径为0.019英寸或更小的微量植入物，并且可以使用自密封方法将其递送至眼睛。提供了制造植入物和微量植入物的方法，其在非常窄的公差范围内产生高度均匀的植入物和微量植入物的批次。

7. 发明申请

US20050048099A1 Ocular implant made by a double extrusion process 审中-公开
标题翻译：通过双重挤压工艺制造的眼部植入物
公开(公告)号：US20050048099A1
公开(公告)日：2005-03-03
申请号：US10918597
申请日：2004-08-13
申请人： Jane-Guo Shiah , Rahul Bhagat , Thierry Nivaggioli , Lin Peng , David Chou , David Weber
发明人： Jane-Guo Shiah , Rahul Bhagat , Thierry Nivaggioli , Lin Peng , David Chou , David Weber
IPC分类号： A61K9/00 , A61K9/20 , A61K9/22 , A61K31/56 , A61F2/00
CPC分类号： A61K31/573 , A61F9/0017 , A61K9/0051 , A61K9/1647 , A61K9/1694 , A61K9/204 , A61K31/56
摘要： The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
摘要翻译：本发明提供了适于植入眼部区域的可生物降解的植入物以及用于治疗眼睛的医学状况的方法。植入物由亲水末端和疏水末端PLGA的混合物形成，并且将活性剂递送到眼部区域而没有高突释。

8. 发明申请

US20080107712A1 OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCESS 有权
公开(公告)号：US20080107712A1
公开(公告)日：2008-05-08
申请号：US11931954
申请日：2007-10-31
申请人： Jane-Guo Shiah , Rahul Bhagat , Wendy Blanda , Thierry Nivaggioli , Lin Peng , David Chou , David Weber
发明人： Jane-Guo Shiah , Rahul Bhagat , Wendy Blanda , Thierry Nivaggioli , Lin Peng , David Chou , David Weber
IPC分类号： A61K9/00 , A61K31/56
CPC分类号： A61K31/573 , A61F9/0017 , A61K9/0051 , A61K9/1647 , A61K9/1694 , A61K9/204 , A61K31/56
摘要： The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.

9. 植物专利

USPP27642P3 Vaccinium plant named ‘Winter Bell’ 有权
标题翻译：牛痘植物名为“冬眠”
公开(公告)号：USPP27642P3
公开(公告)日：2017-02-07
申请号：US14121437
申请日：2014-09-08
申请人： David Weber
发明人： David Weber
IPC分类号： A01H5/08
摘要： A new and distinct Vaccinium spp. cultivar named ‘WINTER BELL’ is disclosed, characterized by a semi-upright plant habit, vigorous growth and semi-deciduous habit in Florida. The new variety shows tolerance for wetter soil conditions. Fruit yield is exceptionally high, with fruit ripening early, with first harvest in mid to late March. Fruit is somewhat bell-shaped with good size and an attractive waxy coating. The new variety is a Vaccinium, and is normally used as an ornamental garden or landscape plant.
摘要翻译：一种新的和不同的牛痘属披露了名为“冬季贝尔”的品种，其特征在于佛罗里达州的半直立植物习性，旺盛的生长和半脱落习惯。新品种显示了对湿润土壤条件的耐受性。果实产量异常高，果实成熟早熟，3月中下旬首次收获。水果有点钟形，尺寸好，有吸引力的蜡质涂层。新品种是牛痘，通常用作观赏花园或景观植物。

10. 发明授权

US08722624B2 Alpha-1-antitrypsin compositions and methods of use 有权
标题翻译： α-1-抗胰蛋白酶组合物和使用方法
公开(公告)号：US08722624B2
公开(公告)日：2014-05-13
申请号：US13385642
申请日：2012-02-28
申请人： Scott M Kee , Paul I Cook , James R Smith , Robert Kling , Scott A Fowler , David Weber
发明人： Scott M Kee , Paul I Cook , James R Smith , Robert Kling , Scott A Fowler , David Weber
IPC分类号： A61K38/17
CPC分类号： A61K38/57 , A61K9/19 , B01D15/327 , B01D15/363 , C07K14/8125 , G01N30/461
摘要： A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as a Cohn fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as a dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitant. Separation of the solid adsorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described.
摘要翻译：提供了从含有AAT的蛋白质混合物如Cohn馏分IV沉淀物中纯化α-1-抗胰蛋白酶（AAT）的流线型方法。在本发明的方法中，污染蛋白质通过用不影响AAT的还原剂如二硫醇裂解二硫键而不稳定。然后将不稳定的蛋白质优先吸附在固体蛋白质吸附材料上，而不加入作为沉淀剂的盐。固体吸附剂与溶液的分离留下直接适用于色谱纯化的纯化AAT溶液，而不需像现有技术方法那样进行广泛的脱盐。还描述了一种以商业规模提供高产量的药物级AAT的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式